Yang-Min Xie
Shantou University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yang-Min Xie.
International Journal of Cancer | 2009
Jian-Jun Xie; Li-Yan Xu; Yang-Min Xie; Haihua Zhang; Wei-Jia Cai; Fei Zhou; Zhong-Ying Shen; En-Min Li
Ezrin, which crosslinks the cytoskeleton and plasma membrane, is involved in the growth and metastatic potential of cancer cells. Ezrin expression in esophageal squamous cell carcinoma (ESCC) was described recently, but its roles and the underlying mechanism(s) remain unclear. In our study, we first showed that ezrin in ESCC cell is expressed in the nucleus as well as in the cytoplasm and plasma membrane. Then, by using RNAi, we revealed that interference of ezrin expression suppressed the growth, adhesion and invasiveness of ESCC cells. Tumorigenesis experiments revealed that ezrin may directly regulate tumor formation in vivo. To explore the molecular mechanisms through which ezrin contributes to the proliferation and invasiveness of ESCC cells, we used cDNA microarrays to analyze ezrin knockdown cells and the control cells; of 39,000 genes examined, 297 were differentially expressed upon ezrin knockdown, including some proliferation‐ and invasiveness‐related genes such as ATF3, CTGF and CYR61. Furthermore, pathway analysis showed that ezrin knockdown led to decreased activation of the TGF‐β and MAPK pathways, and ezrin‐mediated cell invasiveness alteration was dependent on the activation of these pathways. Finally, immunohistochemical staining on 80 ESCC specimens and 50 normal esophageal mucosae revealed that the expression levels of 3 altered genes involved in the regulation of cell proliferation and tumor metastasis, including CTGF, CYR61 and ATF3, were altered in ESCCs, and their expression pattern correlated with ezrin expression. Taken together, we propose that ezrin might function in the growth and invasiveness of ESCC cells through the MAPK and TGF‐β pathways.
The Journal of Pathology | 2013
Wang-Kai Fang; Lian-Di Liao; Li-Yan Li; Yang-Min Xie; Xiu-E Xu; Wei-Jiang Zhao; Jian-Yi Wu; Meng-Xiao Zhu; Zhi-Yong Wu; Ze-Peng Du; Bing-Li Wu; Dong Xie; Ming-Zhou Guo; Li-Yan Xu; En-Min Li
In contrast to the well‐recognized loss of adherens junctions in cancer progression, the role of desmosomal components in cancer development has not been well explored. We previously demonstrated that desmocollin‐2 (DSC2), a desmosomal cadherin protein, is reduced in oesophageal squamous cell carcinoma (ESCC), and is associated with enhanced tumour metastasis and poor prognosis. Here, we report that restoration of DSC2 in ESCC cells impeded cell migration and invasion both in vitro and in vivo, whereas siRNA‐mediated suppression of DSC2 expression increased cell motility. In E‐cadherin‐expressing ESCC cells, DSC2 restoration strengthened E‐cadherin‐mediated adherens junctions and promoted the localization of β‐catenin at these junctions, which indirectly inhibited β‐catenin‐dependent transcription. These effects of DSC2 were not present in EC109 cells that lacked E‐cadherin expression. ESCC patients with tumours that had reduced E‐cadherin and negative DSC2 had poorer clinical outcomes than patients with tumours that lacked either E‐cadherin or DSC2, implying that the invasive potential of ESCC cells was restricted by both DSC2 and E‐cadherin‐dependent junctions. Further studies revealed that DSC2 was a downstream target of miR‐25. Enhanced miR‐25 promoted ESCC cell invasiveness, whereas restoration of DSC2 abolished these effects. Collectively, our work suggests that miR‐25‐mediated down‐regulation of DSC2 promotes ESCC cell aggressiveness through redistributing adherens junctions and activating beta‐catenin signalling. Copyright
International Journal of Molecular Medicine | 2011
Jian-Jun Xie; Li-Yan Xu; Yang-Min Xie; Ze-Peng Du; Cai-Hua Feng; Hui Dong; En-Min Li
Cysteine-rich 61 (Cyr61), a secreted protein which belongs to the CCN family, has been found to be differentially expressed in many cancers and to be involved in tumor progression. The expression of Cyr61 in esophageal squamous cell carcinoma (ESCC) has only recently been described, but the roles of Cyr61 in ESCC cells still remained unclear. In this study, we have shown that there are high levels of Cyr61 in ESCC cell lines. Furthermore, using RNA interference (RNAi), we stably silenced the expression of Cyr61 in EC109 cells, an ESCC cell line. The colony formation, MTT, cell migration, cell invasiveness and cell adhesion assays were employed to address the roles of Cyr61 in the growth, migration and adhesion of ESCC cells. The results have shown that Cyr61 knockdown by RNAi leads to a significant reduction of colony formation and cell growth. The migration and invasiveness ability of EC109 cells were also suppressed with the Cyr61 down-regulation. Furthermore, the adhesion of the EC109 cells was decreased in the Cyr61 knockdown cells compared to the control cells. Taken together, our data suggest that Cyr61 may play crucial roles in regulating neoplasm progression of ESCC.
Cancer Prevention Research | 2013
Jian Hou; Lian-Di Liao; Yang-Min Xie; Fa-Min Zeng; Xia Ji; Bo Chen; Li-Yan Li; Meng-Xiao Zhu; Cui-Xia Yang; Qing-Zhao; Tao Chen; Xiu-E Xu; Jian Shen; Ming-Zhou Guo; En-Min Li; Li-Yan Xu
In animals ranging from fish to mice, the function of DACT2 as a negative regulator of the TGF-β/Nodal signal pathway is conserved in evolution, indicating that it might play an important role in human cancer. In this study, we showed that tumors with higher DACT2 protein level were correlated with better differentiation and better survival rate in patients with esophageal squamous cell carcinoma. Restored expression of DACT2 significantly inhibited growth, migration, and invasion of ESCC cells in vitro, and reduced tumorigenicity in vivo. Furthermore, when DACT2 expression was restored, the activity of TGF-β/SMAD2/3 was suppressed via both proteasome and lysosomal degradation pathways, leading to F-actin rearrangement that might depend on the involvement of cofilin and ezrin–redixin–moesin (ERM) proteins. Taken together, we propose here that DACT2 serves as a prognostic marker that reduces tumor cell malignancy by suppressing TGF-β signaling and promotes actin rearrangement in ESCC. Cancer Prev Res; 6(8); 791–800. ©2013 AACR.
Human Pathology | 2016
Ying Zhu; Meng-Xiao Zhu; Xiao-Dan Zhang; Xiu-E Xu; Zhi-Yong Wu; Lian-Di Liao; Li-Yan Li; Yang-Min Xie; Jian-Yi Wu; Hai-Ying Zou; Jian-Jun Xie; En-Min Li; Li-Yan Xu
Epigenetic alterations, including DNA methylation and histone modifications, are involved in the regulation of cancer initiation and progression. SET and MYND domain-containing protein 3 (SMYD3), a methyltransferase, plays an important role in transcriptional regulation during human cancer progression. However, SMYD3 expression and its function in esophageal squamous cell carcinoma (ESCC) remain unknown. In this study, SMYD3 expression was studied by immunohistochemistry in a tumor tissue microarray from 131 cases of ESCC patients. Statistical analysis showed that overall survival of patients with high SMYD3 expressing in primary tumors was significantly lower than that of patients with low SMYD3-expressing tumors (P = .008, log-rank test). Increased expression of SMYD3 was found to be associated with lymph node metastasis in ESCC (P = .036) and was an independent prognostic factor for poor overall survival (P = .025). RNAi-mediated knockdown of SMYD3 suppressed ESCC cell proliferation, migration, and invasion in vitro and inhibited local tumor invasion in vivo. SMYD3 regulated transcription of EZR and LOXL2 by directly binding to the sequences of the promoter regions of these target genes, as demonstrated by a chromatin immunoprecipitation assay. Immunohistochemical staining of ESCC tissues also confirmed that protein levels of EZR and LOXL2 positively correlated with SMYD3 expression, and the Spearman correlation coefficients (rs) were 0.78 (n = 81; P < .01) and 0.637 (n = 103; P < .01), respectively. These results indicate that SMYD3 enhances tumorigenicity in ESCC through enhancing transcription of genes involved in proliferation, migration, and invasion.
Biochimica et Biophysica Acta | 2015
Ze-Peng Du; Bing-Li Wu; Yang-Min Xie; Ying-Li Zhang; Lian-Di Liao; Fei Zhou; Jian-Jun Xie; Fa-Min Zeng; Xiu-E Xu; Wang-Kai Fang; En-Min Li; Li-Yan Xu
Lipocalin 2 (LCN2) is a poor prognostic factor in esophageal squamous cell carcinoma (ESCC), however its functional roles and molecular mechanisms of action remain to be clarified. Here, we described the functions and signaling pathways for LCN2 in ESCC. Overexpression of LCN2 in ESCC cells accelerated cell migration and invasion in vitro, and promoted lung metastasis in vivo. Blocking LCN2 expression inhibited its pro-oncogenic effect. Either overexpression of LCN2 or treatment with recombinant human LCN2 protein enhanced the activation of MEK/ERK pathway, which in turn increases endogenous LCN2 to increase MMP-9 activity. The decreased p-cofilin and increased p-ERM induced by pERK1/2 cause the cytoskeleton F-actin rearrangement and alter the behavior of ESCC cells mediated by LCN2. As a consequence, activation of MMP-9 and the rearrangement of F-actin throw light on the mechanisms for LCN2 in ESCC. These results imply that LCN2 promotes the migration and invasion of ESCC cells through a novel positive feedback loop.
PLOS ONE | 2015
Xiao-Dan Zhang; Jian-Jun Xie; Lian-Di Liao; Lin Long; Yang-Min Xie; En-Min Li; Li-Yan Xu
The membrane-cytoskeleton link organizer ezrin may be the most “dramatic” tumor marker, being strongly over-expressed in nearly one-third of human malignancies. However, the molecular mechanisms of aberrant ezrin expression still need to be clarified. Ezrin, encoded by the VIL2 gene, has two transcript variants that differ in the transcriptional start site (TSS): V1 and V2. Both V1 and V2 encode the same protein. Here, we found that 12-O-tetradecanoylphorbol-13-acetate (TPA) induced over-expression of human VIL2 in esophageal squamous cell carcinoma (ESCC) cells. Furthermore, VIL2 V1 but not V2 was up-regulated after TPA stimulation in a time-dependent manner. AP-1 and Sp1 binding sites within the promoter region of VIL2 V1 acted not only as basal transcriptional elements but also as a composite TPA-responsive element (TRE) for the transcription of VIL2 V1. TPA stimulation enhanced c-Jun and Sp1 binding to the TRE via activation of the ERK1/2 pathway and increased protein levels of c-Jun, c-Fos, and Sp1, resulting in over-expression of VIL2 V1, whereas the MEK1/2 inhibitor U0126 blocked these events. Finally, we showed that TPA promoted the migration of ESCC cells whereas MEK1/2 inhibitor or ezrin silencing could partially inverse this alteration. Taken together, these results suggest that TPA is able to induce VIL2 V1 over-expression in ESCC cells by activating MEK/ERK1/2 signaling and increasing binding of Sp1 and c-Jun to the TRE of the VIL2 V1 promoter, and that VIL2 is an important TPA-induced effector.
Journal of Proteomics | 2015
Li-Yan Li; Kai Zhang; Hong Jiang; Yang-Min Xie; Lian-Di Liao; Bo Chen; Ze-Peng Du; Pi-Xian Zhang; Hong Chen; Wei Huang; Wei Jia; Hui-Hui Cao; Wei Zheng; En-Min Li; Li-Yan Xu
UNLABELLED High-throughput proteomics has successfully identified thousands of proteins as potential therapeutic targets during investigations into mechanisms of drug action. A novel macrolide analog, denoted F806, is a potential antitumor drug. Here, using the quantitative proteomic approach of stable isotope labeling with amino acids in cell culture (SILAC) coupled to high-resolution mass spectrometry (MS), we characterize the F806-regulating protein profiles and identify the potential target molecules or pathways of F806 in esophageal squamous cell carcinoma (ESCC) cells. From a total of 1931 quantified proteins, 181 proteins were found to be down-regulated (FDR p-value<0.1, H/L ratio<0.738), and 119 proteins were up-regulated (FDR p-value<0.1, H/L ratio>1.156). Among the down-regulated proteins, we uncovered the over- and under-represented protein clusters in biological process and molecular function respectively by Gene Ontology analysis. Furthermore, down-regulated and up-regulated proteins were significantly enriched in 37 pathways and 60 sub-pathways by bioinformatic analysis (FDR p-value<0.1), while a down-regulated molecule growth factor receptor-bound protein 2 (GRB2) was a prominent node in fourteen cell proliferation-related sub-pathways. We concluded that GRB2 downregulation would be a potential target of F806 in ESCC cells. BIOLOGICAL SIGNIFICANCE This study used SILAC-based quantitative proteomics screen to systematically characterize molecular changes induced by a novel macrolide analog F806 in esophageal squamous cell carcinoma (ESCC) cells. Followed by bioinformatic analyses, signal pathway networks generated from the quantified proteins, would facilitate future investigation into the further mechanisms of F806 in ESCC cells. Notably, it provided information that growth factor receptor-bound protein 2 (GRB2) would be a prominent node in the F806-targeted cell proliferation network.
The International Journal of Biochemistry & Cell Biology | 2017
Li-Yan Li; Ying-Hua Xie; Yang-Min Xie; Lian-Di Liao; Xiu-E Xu; Qiang Zhang; Fa-Min Zeng; Li-Hua Tao; Wenming Xie; Jian-Jun Xie; Li-Yan Xu; En-Min Li
BACKGROUND Ezrin, links the plasma membrane to the actin cytoskeleton, and plays an important role in the development and progression of human esophageal squamous cell carcinoma (ESCC). However, the roles of ezrin S66 phosphorylation in tumorigenesis of ESCC remain unclear. METHODS Distribution of ezrin in membrane and cytosol fractions was examined by analysis of detergent-soluble/-insoluble fractions and cytosol/membrane fractionation. Both immunofluorescence and live imaging were used to explore the role of ezrin S66 phosphorylation in the behavior of ezrin and actin in cell filopodia. Cell proliferation, migration and invasion of ESCC cells were investigated by proliferation and migration assays, respectively. Tumorigenesis, local invasion and metastasis were assessed in a nude mouse model of regional lymph node metastasis. RESULTS Ezrin S66 phosphorylation enhanced the recruitment of ezrin to the membrane in ESCC cells. Additionally, non-phosphorylatable ezrin (S66A) significantly prevented filopodia formation, as well as caused a reduction in the number, length and lifetime of filopodia. Moreover, functional experiments revealed that expression of non-phosphorylatable ezrin (S66A) markedly suppressed migration and invasion but not proliferation of ESCC cells in vitro, and attenuated local invasion and regional lymph node metastasis, but not primary tumor growth of ESCC cells in vivo. CONCLUSION Ezrin S66 phosphorylation enhances filopodia formation, contributing to the regulation of invasion and metastasis of esophageal squamous cell carcinoma cells.
Journal of Nutrition | 2018
Lin Long; Jian-Zhong He; Ye Chen; Xiu-E Xu; Lian-Di Liao; Yang-Min Xie; En-Min Li; Li-Yan Xu
Background Riboflavin is an essential component of the human diet and its derivative cofactors play an established role in oxidative metabolism. Riboflavin deficiency has been linked with various human diseases. Objective The objective of this study was to identify whether riboflavin depletion promotes tumorigenesis. Methods HEK293T and NIH3T3 cells were cultured in riboflavin-deficient or riboflavin-sufficient medium and passaged every 48 h. Cells were collected every 5 generations and plate colony formation assays were performed to observe cell proliferation. Subcutaneous tumorigenicity assays in NU/NU mice were used to observe tumorigenicity of riboflavin-depleted HEK293T cells. Mechanistically, gene expression profiling and gene ontology analysis were used to identify abnormally expressed genes induced by riboflavin depletion. Western blot analyses, cell cycle analyses, and chromatin immunoprecipitation were used to validate the expression of cell cycle-related genes. Results Plate colony formation of NIH3T3 and HEK293T cell lines was enhanced >2-fold when cultured in riboflavin-deficient medium for 10-20 generations. Moreover, we observed enhanced subcutaneous tumorigenicity in NU/NU mice following injection of riboflavin-depleted compared with normal HEK293T cells (55.6% compared with 0.0% tumor formation, respectively). Gene expression profiling and gene ontology analysis revealed that riboflavin depletion induced the expression of cell cycle-related genes. Validation experiments also found that riboflavin depletion decreased p21 and p27 protein levels by ∼20%, and increased cell cycle-related and expression-elevated protein in tumor (CREPT) protein expression >2-fold, resulting in cyclin D1 and CDK4 levels being increased ∼1.5-fold, and cell cycle acceleration. We also observed that riboflavin depletion decreased intracellular riboflavin levels by 20% and upregulated expression of riboflavin transporter genes, particularly SLC52A3, and that the changes in CREPT and SLC52A3 correlated with specific epigenetic changes in their promoters in riboflavin-depleted HEK293T cells. Conclusion Riboflavin depletion contributes to HEK293T and NIH3T3 cell tumorigenesis and may be a risk factor for tumor development.